Showing 4531-4540 of 5771 results for "".
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- Roche’s Actemra/RoActemra Cuts Need for Ventilator Use in COVID-19 Pneumoniahttps://modernod.com/news/roches-actemra-roactemra-cuts-need-for-ventilator-use-in-covid-19-pneumonia/2478299/Roche announced results from the EMPACTA study on Friday, showing that patients with COVID-19-associated pneumonia who had Actemra/RoActemra (tocilizumab) added to standard care were 44% less likely to progress to mechanical ventilation or death compared to placebo plus standard care, meeting the
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- GenSight Biologics Submits EU Marketing Authorization Application for LHON Gene Therapy Lumevoqhttps://modernod.com/news/gensight-biologics-submits-eu-marketing-authorization-application-for-lhon-gene-therapy-lumevoq/2478287/GenSight Biologics announced that it has submitted the Marketing Authorization Application (MAA) for its lead product Lumevoq to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation
- Aviceda Therapeutics Appoints Biopharma and Business Veterans to its Board of Directorshttps://modernod.com/news/aviceda-therapeutics-appoints-biopharma-and-business-veterans-to-its-board-of-directors/2478284/Aviceda Therapeutics has announce the appointment of Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA, to their board of directors, effective immediately. Aviceda is a preclinical stage biotech company focused on the next generation of glyco-immune therapeutics utilizing the Glyco-Code technolog
- European Medicines Agency (EMA) Approves Safety Label Update for Novartis’ Beovuhttps://modernod.com/news/european-medicines-agency-ema-approves-safety-label-update-for-novartis-beovu/2478279/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion.1 Typically, the
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- Surgical Repair of Chronic Refractory Macular Holes Using AmnioGraft Cryopreserved Amniotic Membranehttps://modernod.com/news/surgical-repair-of-chronic-refractory-macular-holes-using-amniograft-cryopreserved-amniotic-membrane/2478277/Bio-Tissue announced the case series outcome of surgical repair of large macular holes using AmnioGraft Cryopreserved Amniotic Membrane. Results have shown that the placement of AmnioGraft may be a feasible alternative to conventional surgical methods to improve anatomic and visual outcomes.